Emerging Markets Are Next Turn In Sanofi Consumer Health Growth
Executive Summary
Sanofi's consumer health sales were off 1%, at $1.4bn, during its latest quarter compared to a corresponding year-ago period, with inclusion of Boehringer's OTC drug and nutritional product brand revenues. But for Sanofi's legacy consumer products only, sales were up 42.5%.
You may also be interested in...
Sanofi's Consumer Business Starts 2017 With 'Reassuring' Momentum
Sanofi consumer products head Alan Main says BI's brands will "lift Sanofi into leadership positions in attractive OTC categories, namely the vitamins and minerals supplements market, digestive products, cough and cold as well as pain medications."
Sanofi Adds Consumer Brands, Grows Footprint With Boehringer Ingelheim Deal
BI international brands including Mucoangin cough suppressant and Dulcolax constipation treatment and US heartburn remedy Zantac would join Sanofi's consumer portfolio including US brands Allegra Allergy antihistamines and Nasacort Allergy 24HR nasal decongestant in the firm's proposed asset swap.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.